相关实验视频
Updated: Jun 26, 2026

07:57
A New Method for Inducing a Depression-Like Behavior in Rats
Published on: February 22, 2018
20.8K
一种选择性核因子-kB抑制剂,JSH-23,表现出类似抗抑郁药的效果,并减少大脑炎症在老鼠
Ahmad Nassar1, Jacob Kaplanski1, Abed N Azab1,2
1Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Pharmaceuticals (Basel, Switzerland)
|October 26, 2024
概括
该研究发现,NF-κB抑制剂JSH-23降低了炎症,并在老鼠中表现出类似抗抑郁药的效果. 这些发现表明NF-kB是抑郁症治疗的潜在点.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 核因子卡帕B (NF-κB) 在情绪障碍的病理生理学中起作用.
- 炎症越来越被认为是导致抑郁和躁狂的因素.
研究的目的:
- 研究选择性NF-κB抑制剂JSH-23对大鼠炎症和情绪障碍模型的影响.
- 评估JSH-23对大脑炎症标志物的影响.
主要方法:
- 鼠被用JSH-23治疗,以评估对脂聚糖 (LPS) 诱导的炎症的抗炎作用.
- 行为测试 (糖消费,强迫游泳,安非他命过活) 用于模拟抑郁和躁狂.
- 测量了炎症媒介的水平 (干白素-6,前列腺素E2,核脂-p65,瘤缩因子-α).
主要成果:
- JSH-23表现出强大的抗炎作用,减少LPS诱导的低温和促炎媒介.
- 长期的JSH-23治疗产生了类似抗抑郁药的效果,增加了糖的消耗和减少了不运动.
- JSH-23没有影响胺诱导的多动性,这表明没有抗躁狂作用.
结论:
- 通过JSH-23抑制NF-κB可缓解炎症,并在动物模型中表现出类似抗抑郁药的特性.
- 这些发现强调NF-κB作为抑郁症的有希望的治疗点.
相关概念视频
NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

